<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990181</url>
  </required_header>
  <id_info>
    <org_study_id>FePPHH</org_study_id>
    <nct_id>NCT03990181</nct_id>
  </id_info>
  <brief_title>Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement</brief_title>
  <official_title>Testing the Efficacy of a Natural Polyphenol Supplement to Inhibit Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis: a Stable Isotope Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigação em Imunologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyphenolic compounds are very strong Inhibitors of non-heme iron absorption, as they form
      insoluble complexes with ferrous iron. Patients with hereditary hemochromatosis (HH) have an
      increased intestinal non-heme iron absorption due to a genetic mutation in the regulatory
      pathway, leading to excess iron in the body. This study investigates the inhibitory effect of
      a natural polyphenol Supplement in participants with HH.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in the isotopic ratio of iron in blood at week 2</measure>
    <time_frame>baseline, 2 weeks</time_frame>
    <description>The change in the isotopic ratio of iron will be measured after administration of a test meal/drink including iron isotopes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in the isotopic ratio of iron in blood at week 4</measure>
    <time_frame>2 weeks, 4 weeks</time_frame>
    <description>The change in the isotopic ratio of iron will be measured after administration of a test meal/drink including iron isotopes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin concentration (µg/L)</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>to assess iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron concentration (µg/dL)</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>to assess iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble transferrin receptor (mg/L)</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>to assess iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation in %</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>to calculate percent of transferrin that has iron bound to it; Plasma iron and transferrin saturation will be combined to calculate transferrin saturation (ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/dL)</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>to assess blood volume based on weight, height, and Hb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (mg/L)</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>identify acute inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alpha-1-glycoprotein (g/L)</measure>
    <time_frame>baseline, weeks 2, and 4</time_frame>
    <description>identify chronic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hepcidin (nM)</measure>
    <time_frame>baseline, and weeks 2</time_frame>
    <description>the major regulator of non-heme iron absorption</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Iron Metabolism Disorders</condition>
  <condition>Iron Overload</condition>
  <condition>Polyphenols</condition>
  <arm_group>
    <arm_group_label>Meal &amp; natural polyphenol supplement (NPPS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drink &amp; natural polyphenol supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meal &amp; control supplement (CS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drink &amp; control supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>meal matrix &amp; NPPS</intervention_name>
    <description>Test meal consumed with the natural polyphenol supplement</description>
    <arm_group_label>Meal &amp; natural polyphenol supplement (NPPS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>meal matrix &amp; CS</intervention_name>
    <description>Test meal consumed with the control supplement</description>
    <arm_group_label>Meal &amp; control supplement (CS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>no-matrix &amp; NPPS</intervention_name>
    <description>Test drink consumed with the natural polyphenol supplement</description>
    <arm_group_label>Drink &amp; natural polyphenol supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>no-matrix &amp; CS</intervention_name>
    <description>Test drink consumed with the control supplement</description>
    <arm_group_label>Drink &amp; control supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous for C282Y mutation in HFE (hemochromatosis) gene

          -  Written informed consent

          -  Age 18-65 y

          -  Not pregnant or lactating

          -  Body weight &lt; 75 kg

          -  Body mass index (BMI) between 18.5 and 25 kg/m2

          -  No acute illness/infection (self-reported)

          -  No metabolic or gastrointestinal disorders, eating disorders or food allergy to the
             ingredients of the test meal (self-reported)

          -  No scheduled phlebotomy throughout the study period

          -  The last phlebotomy will be at least 4 weeks prior first test meal administration

          -  No use of medications affecting iron absorption or metabolism during the study

          -  No intake of mineral/vitamin supplements 2 weeks before the first study day and during
             the study

          -  Participation in any other clinical study within the last 30 days

          -  Expected to comply with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael B Zimmermann, Prof. Dr.</last_name>
    <phone>+41 44 632 86 57</phone>
    <email>michael.zimmermann@hest.ethz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Bürkli, MSc</last_name>
    <phone>+41 44 632 86 39</phone>
    <email>simone.buerkli@hest.ethz.ch</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Prof. Michael B. Zimmermann</investigator_full_name>
    <investigator_title>Head of the Laboratory of Human Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemochromatosis</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Iron Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

